

5

13

We claim:

10

1. A chemical compound comprising first and second hsp-binding moieties which bind to the pocket of hsp90 with which ansamycin antibiotics bind, said binding moieties being connected to one another by a linker.

15

2. The chemical compound according to claim 1, wherein the first hsp-binding moiety is an ansamycin antibiotic.

20

3. The chemical compound according to claim 2, wherein the first and second hsp-binding moieties are each an ansamycin antibiotic.

25

4. The chemical compound of claim 3, wherein at least one of the hsp-binding moieties is geldanamycin.

30

5. The chemical compound of claim 4, wherein the first and second hsp-binding moieties are geldanamycin.

35

6. The chemical compound of claim 5, wherein the linker has a length of 4 to 7 carbons atoms.

40

7. The chemical compound of claim 6, wherein the linker has a length of 4 carbon atoms.

45

8. The chemical compound of claim 1, wherein at least one of the hsp-binding moieties is geldanamycin.

50

9. The chemical compound of claim 8, wherein the first and second hsp-binding moieties are geldanamycin.

55

10. The chemical compound of claim 9, wherein the linker has a length of 4 to 7 carbons atoms.

55

5

14

11. The chemical compound of claim 10, wherein the linker has a length of 4 carbon atoms.

10

12. A method for destruction of cells expressing a HER-family tyrosine kinase, comprising administering to the cells a chemical compound according to any of claims 1-11.

15

13. A method for treating cancer in a patients suffering from cancer, comprising administering to the patient a therapeutic composition comprising a chemical compound according to any of claims 1-11.

14. The method of claim 13, wherein the cancer is an HER-positive cancer.

20
25
30
35

add
B1

add
C1

40

45

50

SUBSTITUTE SHEET (RULE 26)

55